Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

JAK2 mutations across a spectrum of venous thrombosis cases.

American journal of clinical pathology - 1 Jul 2010

Shetty Shrimati, Kulkarni Bipin, Pai Navin, Mukundan Preeti, Kasatkar Priyanka, Ghosh Kanjaksha

Abstract excerpt

The JAK2(V617F)mutation is recurrent in polycythemia vera and essential thrombocythemia, which are myeloproliferative neoplasms frequently associated with arterial and venous thromboembolism. It has also been reported as a marker for occult myeloproliferative disorder (MPD) in patients with splanchnic venous thrombosis. Limited data are available regarding the prevalence of the JAK2(V617F) mutation in patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Budd-Chiari Syndrome
Share to Child, Preschool
Share to Genetic Markers

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Testing

Share to Infant

Share to Janus Kinase 2

Share to Portal Vein

Share to Venous Thrombosis

Source

Identifiers

PMID: 20551270
DOI: 10.1309/AJCP7VO4HAIZYATP

Genes

JAK2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

JAK2 mutations across a spectrum of venous thrombosis cases.PMID 20551270Read ↗

Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders.Semantic proximity Read ↗

Low prevalence of JAK2 V617F mutation in patients with thrombosis and normal blood counts: a retrospective impact study.Semantic proximity Read ↗

Is the JAK2 V617F mutation a hallmark for different forms of thrombosis?Semantic proximity Read ↗

JAK2V617F mutation in patients with thrombosis: to screen or not to screen?Semantic proximity Read ↗

Prevalence of Janus Kinase 2 mutations in patients with unusual site venous thrombosis.Semantic proximity Read ↗

[Thrombosis in myeloproliferative neoplasms].Semantic proximity Read ↗

JAK2V617F mutation screening as part of the hypercoagulable work-up in the absence of splanchnic venous thrombosis or overt myeloproliferative neoplasm: assessment of value in a series of 664 consecutive patients.Semantic proximity Read ↗

Splanchnic Vein Thrombosis in Myelofibrosis-An Underappreciated Hallmark of Disease Phenotype.Semantic proximity Read ↗

JAK2 mutation-related disease and thrombosis.Semantic proximity Read ↗

The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases.Semantic proximity Read ↗

Splanchnic vein thrombosis in myeloproliferative neoplasms.Semantic proximity Read ↗

Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.